Shorter-acting GLP-1 RAs tend to delay gastric emptying more significantly than long-acting GLP-1 RAs, and long-acting agents generally do not increase the risk of long-term GERD-related outcomes (15). The gene discussed is GCG; the disease is gastroesophageal reflux disease.